Deutsche Post AG: Release according to Article 40 Section 1 of ...
AUSTRIACARD HOLDINGS AG: Notification and public disclosure of ...
Director / PDMR Shareholding. Molten Ventures Plc / GB00BY7QYJ50 ...
Deutsche Post AG: Release according to Article 40 Section 1 of ...
Mercedes-Benz Group AG: Release according to Article 40 Section ...
HUGO BOSS AG: Release according to Article 40 Section 1 of the ...
Edison issues report on Murray Income Trust (MUT). Edison Investment ...
E.ON SE: Release according to Article 40 Section 1 of the WpHG ...
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for ...
SureWerx selects Intershop to enhance purchasing experience for ...
Turkiye Garanti Bankasi A.S.: Annoucement about the issuance ...
Deutsche Lufthansa AG: Release according to Article 40 Section ...
AMADEUS FIRE AG: Release according to Article 40 Section 1 of ...
LM PAY S.A. Announces Third Quarter 2024 Preliminary Results ...
NORMA Group SE: Release according to Article 40 Section 1 of ...
Covestro AG: Release according to Article 40 Section 1 of the ...
Covestro AG: Release according to Article 40 Section 1 of the ...
MTU Aero Engines AG: Release according to Article 40 Section ...
Covestro AG: Release according to Article 40 Section 1 of the ...
grenke AG: Manfred Piontke, buy
NOTICE OF ANNUAL GENERAL MEETING. Grit Real Estate Income Group ...
Seequent and the International Geothermal Association Partner ...
audius with successful third quarter 2024 - total revenue grows ...
Hardman & Co Investor Forum Research on Shield Therapeutics (STX): ...
DesignInspire opens on December 5 with free admission for the ...
IVU AG publishes Quarterly Report Q3-2024. IVU Traffic Technologies ...
Holding(s) in Company. easyJet plc / GB00B7KR2P84
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivaâs ...
Aurubis AG: Release according to Article 40 Section 1 of the ...
Hamburger Hafen und Logistik AG: Release according to Article ...
Softing AG: Release according to Article 40 Section 1 of the ...
First Patient Treated in Phase I / II Trial in Acute Myeloid ...